Prescription medicine

Revefenacin Brand names: Yupelri

Revefenacin (Yupelri) is a prescription medicine with an FDA approval on record since 2018. No generic is listed; pharmacies paid $17.43 per mL (Yupelri 175 mcg/3 mL solution) in the October 7, 2026 NADAC survey.

No generic listed

Check it at the source: the revefenacin FDA label on DailyMed (effective May 3, 2022, Viatris Specialty LLC); the NDA 210598 record on Drugs@FDA; every revefenacin label on DailyMed.

Highlights of the record

FDA label of May 3, 2022; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026

Used for

From the label: indications and usage
YUPELRI is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Forms and strengths

Solution.

On the market

Earliest approval on file: November 9, 2018 Yupelri, Mylan Ireland Ltd; Drugs@FDA’s file, where older or withdrawn approvals can be missing
Generic approvals: No generic approved
Labelers listed (NDC): 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Last listed patent: October 23, 2039 Yupelri solution; not a generic launch date

Supply and safety

Pharmacy cost (NADAC): $17.43 per mL Yupelri 175 mcg/3 mL solution
Shortage (FDA): No current entry
Recalls by its makers (FDA): No recall recorded
FAERS reports: 812 through July 30, 2026

What is revefenacin used for?

From the label: indications and usage
YUPELRI is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Conditions named in the indications of revefenacin's FDA labels, with every medicine labeled for each:

COPD

FDA pharmacologic class: Anticholinergic.

Source: FDA drug label (YUPELRI), NDA210598 (Mylan Ireland Ltd), as published by Viatris Specialty LLC, effective May 3, 2022 (SPL set 6dfebf04-7c90-436a-9b16-750d3c1ee0a6), via openFDA; the full label on DailyMed

Is there a generic for revefenacin (Yupelri)?

No generic revefenacin is approved (Drugs@FDA, October 8, 2026). Drugs@FDA also holds 2 tentative approvals: the FDA found the generic approvable, but patents or exclusivity keep it from final approval for now.

The Orange Book lists 10 patents for Yupelri solution: the compound patent runs to August 25, 2031, and the last listed entry to October 23, 2039. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.

2018 earliest approval on file
2039 last listed patent

Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)

What do pharmacies pay for revefenacin (Yupelri)?

In CMS's NADAC survey of October 7, 2026, pharmacies paid $17.43 per mL (Yupelri 175 mcg/3 mL solution), up 5% from $16.60 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.

Yupelri 175 mcg/3 mL solution (brand)

$17.49

$13.79

January 2024October 2026

NADAC per unit, October 7, 2026
Strength and form	Brand or generic	Pharmacy cost	30 tablets, or one pen or vial	12-month change
Yupelri 175 mcg/3 mL solution	Brand	$17.43 per mL	n/a	+5%

Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price

What does the revefenacin label say about other medicines?

The revefenacin label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.

Medicine named	Section	What the label says
Cyclosporine	drug interactions	Transporter-related drug interactions: Coadministration of YUPELRI with OATP1B1 and OATP1B3 inhibitors (e.g. rifampicin, cyclosporine, etc.) may lead to an increase in exposure of the active metabolite.

Check revefenacin against other medicines

What do FAERS reports show for revefenacin?

The FDA Adverse Event Reporting System holds 812 reports that list revefenacin among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 72 are coded as a death and 175 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.

Reports received each year

The most reported reactions

Dyspnoea208
Cough (named in the label)57
Headache (named in the label)56
Fatigue53
Death (an outcome recorded in the report)48
Pneumonia47
Chronic Obstructive Pulmonary Disease (a use or a product term, not a reaction)44
Drug Ineffective (a use or a product term, not a reaction)42

Side effects: the label's list and every FAERS reaction

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026

What else is labeled for the same conditions as revefenacin?

15 other medicines are given the same way (respiratory (inhalation)) and in the same FDA class as revefenacin or labeled mainly for the same use (COPD), the same class first. COPD lists all 23 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.

Medicine	Shared indication	Generic labelers (respiratory (inhalation))	Pharmacy cost	Shortage
Albuterol and ipratropium	COPD	14 labelers	$0.0787 per mL 0.5-3(2.5) mg/3 mL	No current entry
Ipratropium	COPD	13 labelers	$0.111 per mL 0.02% solution	No current entry
Budesonide and formoterol and glycopyrrolate	COPD	none listed	$61.41 per gram 160-9-4.8 mcg	No current entry
Fluticasone and umeclidinium and vilanterol	COPD	none listed	$11.12 per unit 100-62.5-25	No current entry
Tiotropium	COPD	none listed	$126.08 per gram 1.25 mcg inhaler	No current entry
Umeclidinium and vilanterol	COPD	none listed	$4.95 per inhaler 62.5-25 mcg inhaler	No current entry
Aclidinium	COPD	none listed	$344.55 per unit 400 mcg inhal	No current entry
Aclidinium and formoterol	COPD	none listed	n/a	No current entry

Every medicine labeled for the same conditions as revefenacin

Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)

What next?

Alternatives to revefenacin: 15 medicines for the same use
Other anticholinergics: the pharmacologic class, with prices and generics
Revefenacin side effects: the label's list beside FAERS reports
Check an interaction: what two or more labels say about each other